Dual Research on Drug Efficacy and Toxicity: A Multidisciplinary Integration Perspective
DOI:
https://doi.org/10.61173/pq667y55Keywords:
List the, keywords covered, in your paperAbstract
In modern society, drugs serve as the most prevalent approach to treating diseases. Nevertheless, while combating illnesses, drugs may also trigger adverse responses in the human body, encompassing side effects, toxic reactions, allergic reactions, secondary reactions, residual effects, and teratogenic effects. Take rifampicin as an example: excessive administration of this drug can lead to acute or chronic toxic damage to the circulatory, respiratory, and nervous systems, as well as disrupt the functions of the liver, kidneys, bone marrow, and endocrine organs.[1] Consequently, identifying the potential toxicity of drugs and safeguarding medication safety have become a crucial component in the process of drug research and development (R&D) and clinical application. As technologies like multi-omics, systems biology, and artificial intelligence (AI) continue to advance, interdisciplinary research has gradually evolved into a new paradigm for assessing drug efficacy and toxicology. This paper aims to explore the synergistic mechanisms underlying drug efficacy and toxicity across multiple biological levels, including molecular, cellular, organ, and systemic levels.
References
[1] World Health Organization. (2017). Guidelines for the safe use of rifampicin in the treatment of tuberculosis. Geneva: WHO Press.
[2] Zhang, Y., Li, J., Wang, H., et al. (2023). Construction of target-toxicity mapping for antitumor drugs via multi-omics integration to guide drug structure optimization. Journal of Pharmaceutical Analysis, 13(4), 589–602.
[3] Sacco, E., Minotti, G., Menna, P., et al. (2015). Cardiotoxicity of targeted anticancer drugs: The need for a multidisciplinary approach. Annals of Oncology, 26(Suppl 5), v204–v212.
[4] Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: Navigating the network. Cell, 129(7), 1261–1274.
[5] Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103–141.
[6] Ingelman-Sundberg, M. (2005). Genetic polymorphisms o f c y t o c h r o m e P 4 5 0 2 D 6 ( C Y P 2 D 6 ) : C l i n i c a l consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal, 5(1), 6–13.
[7] Swain, S. M., Whaley, F. S., & Ewer, M. S. (2000). Cardiotoxicity of the Herceptin (trastuzumab) in a patient with metastatic breast cancer. New England Journal of Medicine, 342(19), 1401–1402.
[8] Chung, C. H., Lipshultz, S. E., Lipsitz, S. R., et al. (2005). Cardiotoxicity associated with imatinib mesylate therapy. Journal of Clinical Oncology, 23(10), 2275–2280.
[9] Chen, S., Zhao, L., Liu, X., et al. (2022). Network pharmacology-based analysis of the toxic mechanism of an antihypertensive drug targeting ADRB2 in cardiomyocytes. British Journal of Pharmacology, 179(15), 3872–3885.
[10] Wang, Q., Zhang, H., Chen, J., et al. (2024). Development and validation of a target-side effect network prediction platform for early risk assessment of new hypoglycemic drugs. Pharmaceutical Research, 41(2), 678–691.
[11] Li, M., Hua, Y., Zhang, S., et al. (2023). Human liver organoids reveal hepatotoxicity of an antibiotic that is undetected in mouse models. Hepatology, 78(3), 1124–1137.
[12] Zhao, Y., Wu, J., Li, D., et al. (2022). Intestinal organoid model identifies intestinal barrier damage induced by an oral anti-inflammatory drug and guides dosage form optimization. Journal of Controlled Release, 345, 89–101.
[13] Liu, C., Yang, H., Wang, Z., et al. (2024). A random forestbased drug-toxicity correlation model for predicting bone marrow suppression of antitumor candidates. Computational Biology and Chemistry, 103, 107789.
[14] Huang, L., Zhang, J., Chen, G., et al. (2023). Natural language processing of global adverse drug reaction reports to identify high-risk populations for hemorrhagic stroke induced by an antidepressant. Pharmacoepidemiology and Drug Safety, 32(5), 612–621.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
